Journal
MOLECULAR MEDICINE
Volume 28, Issue 1, Pages -Publisher
SPRINGER
DOI: 10.1186/s10020-022-00492-7
Keywords
RCAN1; Calcineurin; Cancer therapy
Funding
- National Natural Science Foundation of China [81830089, 81871925, 81672337]
- National Key Research and Development Program [2019YFC1316000]
- Key Research and Development Program of Zhejiang Province [2020C03117]
Ask authors/readers for more resources
This review highlights the crucial role of regulator of calcineurin 1 (RCAN1) in the pathogenesis of cancer and its interaction with calcineurin. High expression of RCAN1 inhibits tumor progression, except for hypopharyngeal and laryngopharynx cancer. Therefore, targeting RCAN1 may be a promising therapeutic approach for cancer treatment.
Cancer is the leading cause of mortality worldwide. Regulator of calcineurin 1 (RCAN1), as a patent endogenous inhibitor of calcineurin, plays crucial roles in the pathogenesis of cancers. Except for hypopharyngeal and laryngopharynx cancer, high expression of RCAN1 inhibits tumor progression. Molecular antitumor functions of RCAN1 are largely dependent on calcineurin. In this review, we highlight current research on RCAN1 characteristics, and the interaction between RCAN1 and calcineurin. Moreover, the dysregulation of RCAN1 in various cancers is reviewed, and the potential of targeting RCAN1 as a new therapeutic approach is discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available